Limits...
A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers.

Jokerst JV, Chen Z, Xu L, Nolley R, Chang E, Mitchell B, Brooks JD, Gambhir SS - PLoS ONE (2015)

Bottom Line: The results were analyzed with receiver operator characteristic curve analysis.The highest AUC discrimination was achieved with a spondin-2 OR free/total PSA operation--the area under the curve was 0.84 with a p value below 10(-6).This bead-based system offers important advantages in assay building including low cost, high throughput, and rapid identification of an optimal matched antibody pair.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, United States of America.

ABSTRACT
Novel biomarker assays and upgraded analytical tools are urgently needed to accurately discriminate benign prostatic hypertrophy (BPH) from prostate cancer (CaP). To address this unmet clinical need, we report a piezeoelectric/magnetic bead-based assay to quantitate prostate specific antigen (PSA; free and total), prostatic acid phosphatase, carbonic anhydrase 1 (CA1), osteonectin, IL-6 soluble receptor (IL-6sr), and spondin-2. We used the sensor to measure these seven proteins in serum samples from 120 benign prostate hypertrophy patients and 100 Gleason score 6 and 7 CaP using serum samples previously collected and banked. The results were analyzed with receiver operator characteristic curve analysis. There were significant differences between BPH and CaP patients in the PSA, CA1, and spondin-2 assays. The highest AUC discrimination was achieved with a spondin-2 OR free/total PSA operation--the area under the curve was 0.84 with a p value below 10(-6). Some of these data seem to contradict previous reports and highlight the importance of sample selection and proper assay building in the development of biomarker measurement schemes. This bead-based system offers important advantages in assay building including low cost, high throughput, and rapid identification of an optimal matched antibody pair.

No MeSH data available.


Related in: MedlinePlus

Clinical Data Analysis.A) Mean values with standard deviation for the seven biomarkers with BPH, CaP, and post-surgery [39] samples. Units are ng/mL. The p value reported here is the significance between the BPH and CaP samples. AUC values are also given and report discrimination between CaP and BPH. Lower panel presents ROC curves for PSA, SPON2, and PSA OR SPON2. The OR operator increases the AUC to 0.84 from 0.80 for PSA alone.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4589536&req=5

pone.0139484.g005: Clinical Data Analysis.A) Mean values with standard deviation for the seven biomarkers with BPH, CaP, and post-surgery [39] samples. Units are ng/mL. The p value reported here is the significance between the BPH and CaP samples. AUC values are also given and report discrimination between CaP and BPH. Lower panel presents ROC curves for PSA, SPON2, and PSA OR SPON2. The OR operator increases the AUC to 0.84 from 0.80 for PSA alone.

Mentions: We created ROC curves and measured the AUC for all biomarkers using the biopsy-confirmed diagnosis and measured values (Fig 5). The PAP AUC was 0.51; 95% confidence interval 0.43–0.58 with p>0.50. The SPARC AUC was 0.51; 95% confidence interval 0.43 to 0.59 with p>0.50. The CA1 AUC was 0.55; 95% confidence interval 0.47 to 0.63 with p = 0.17. The IL-6sr AUC was 0.57; 95% confidence interval 0.50 to 0.65 with p = 0.06. The SPON2 AUC was 0.76; 95% confidence interval 0.69 to 0.82 with p<0.0001.


A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers.

Jokerst JV, Chen Z, Xu L, Nolley R, Chang E, Mitchell B, Brooks JD, Gambhir SS - PLoS ONE (2015)

Clinical Data Analysis.A) Mean values with standard deviation for the seven biomarkers with BPH, CaP, and post-surgery [39] samples. Units are ng/mL. The p value reported here is the significance between the BPH and CaP samples. AUC values are also given and report discrimination between CaP and BPH. Lower panel presents ROC curves for PSA, SPON2, and PSA OR SPON2. The OR operator increases the AUC to 0.84 from 0.80 for PSA alone.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4589536&req=5

pone.0139484.g005: Clinical Data Analysis.A) Mean values with standard deviation for the seven biomarkers with BPH, CaP, and post-surgery [39] samples. Units are ng/mL. The p value reported here is the significance between the BPH and CaP samples. AUC values are also given and report discrimination between CaP and BPH. Lower panel presents ROC curves for PSA, SPON2, and PSA OR SPON2. The OR operator increases the AUC to 0.84 from 0.80 for PSA alone.
Mentions: We created ROC curves and measured the AUC for all biomarkers using the biopsy-confirmed diagnosis and measured values (Fig 5). The PAP AUC was 0.51; 95% confidence interval 0.43–0.58 with p>0.50. The SPARC AUC was 0.51; 95% confidence interval 0.43 to 0.59 with p>0.50. The CA1 AUC was 0.55; 95% confidence interval 0.47 to 0.63 with p = 0.17. The IL-6sr AUC was 0.57; 95% confidence interval 0.50 to 0.65 with p = 0.06. The SPON2 AUC was 0.76; 95% confidence interval 0.69 to 0.82 with p<0.0001.

Bottom Line: The results were analyzed with receiver operator characteristic curve analysis.The highest AUC discrimination was achieved with a spondin-2 OR free/total PSA operation--the area under the curve was 0.84 with a p value below 10(-6).This bead-based system offers important advantages in assay building including low cost, high throughput, and rapid identification of an optimal matched antibody pair.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California, United States of America.

ABSTRACT
Novel biomarker assays and upgraded analytical tools are urgently needed to accurately discriminate benign prostatic hypertrophy (BPH) from prostate cancer (CaP). To address this unmet clinical need, we report a piezeoelectric/magnetic bead-based assay to quantitate prostate specific antigen (PSA; free and total), prostatic acid phosphatase, carbonic anhydrase 1 (CA1), osteonectin, IL-6 soluble receptor (IL-6sr), and spondin-2. We used the sensor to measure these seven proteins in serum samples from 120 benign prostate hypertrophy patients and 100 Gleason score 6 and 7 CaP using serum samples previously collected and banked. The results were analyzed with receiver operator characteristic curve analysis. There were significant differences between BPH and CaP patients in the PSA, CA1, and spondin-2 assays. The highest AUC discrimination was achieved with a spondin-2 OR free/total PSA operation--the area under the curve was 0.84 with a p value below 10(-6). Some of these data seem to contradict previous reports and highlight the importance of sample selection and proper assay building in the development of biomarker measurement schemes. This bead-based system offers important advantages in assay building including low cost, high throughput, and rapid identification of an optimal matched antibody pair.

No MeSH data available.


Related in: MedlinePlus